263 related articles for article (PubMed ID: 28323493)
1. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer.
Bakhtiary Z; Barar J; Aghanejad A; Saei AA; Nemati E; Ezzati Nazhad Dolatabadi J; Omidi Y
Drug Dev Ind Pharm; 2017 Aug; 43(8):1244-1253. PubMed ID: 28323493
[TBL] [Abstract][Full Text] [Related]
2. Development, In Vitro Characterization, Antitumor and Aerosol Performance Evaluation of Respirable Prepared by Self-nanoemulsification Method.
Naseri N; Zakeri-Milani P; Hamishehkar H; Pilehvar-Soltanahmadi Y; Valizadeh H
Drug Res (Stuttg); 2017 Jun; 67(6):343-348. PubMed ID: 28288490
[TBL] [Abstract][Full Text] [Related]
3. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.
Nemati E; Mokhtarzadeh A; Panahi-Azar V; Mohammadi A; Hamishehkar H; Mesgari-Abbasi M; Ezzati Nazhad Dolatabadi J; de la Guardia M
AAPS PharmSciTech; 2019 Feb; 20(3):120. PubMed ID: 30796625
[TBL] [Abstract][Full Text] [Related]
4. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance.
Ezzati Nazhad Dolatabadi J; Hamishehkar H; Valizadeh H
Drug Dev Ind Pharm; 2015; 41(9):1431-7. PubMed ID: 25220930
[TBL] [Abstract][Full Text] [Related]
5. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
6. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance.
Patil-Gadhe A; Kyadarkunte A; Patole M; Pokharkar V
Eur J Pharm Biopharm; 2014 Sep; 88(1):169-77. PubMed ID: 25078860
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy.
Satari N; Taymouri S; Varshosaz J; Rostami M; Mirian M
Drug Dev Ind Pharm; 2020 Aug; 46(8):1265-1277. PubMed ID: 32594775
[TBL] [Abstract][Full Text] [Related]
8. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo.
Tan S; Wang G
Drug Des Devel Ther; 2017; 11():3519-3529. PubMed ID: 29263650
[TBL] [Abstract][Full Text] [Related]
9. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
10. Co-Spray Dried Mannitol/Poly(amidoamine)-Doxorubicin Dry-Powder Inhaler Formulations for Lung Adenocarcinoma: Morphology, In Vitro Evaluation, and Aerodynamic Performance.
Zhong Q
AAPS PharmSciTech; 2018 Feb; 19(2):531-540. PubMed ID: 28840529
[TBL] [Abstract][Full Text] [Related]
11. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
[TBL] [Abstract][Full Text] [Related]
12. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
[TBL] [Abstract][Full Text] [Related]
13. Microwave-assisted formulation of solid lipid nanoparticles loaded with non-steroidal anti-inflammatory drugs.
Shah RM; Eldridge DS; Palombo EA; Harding IH
Int J Pharm; 2016 Dec; 515(1-2):543-554. PubMed ID: 27789371
[TBL] [Abstract][Full Text] [Related]
14. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
15. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo.
Wang P; Zhang L; Peng H; Li Y; Xiong J; Xu Z
Mater Sci Eng C Mater Biol Appl; 2013 Dec; 33(8):4802-8. PubMed ID: 24094190
[TBL] [Abstract][Full Text] [Related]
16. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib-Loaded Poly(ε-Caprolactone) Nanocapsules Improve In Vitro Cytotoxicity and Anticlonogenic Effects on Human A549 Lung Cancer Cells.
Bruinsmann FA; Buss JH; Souto GD; Schultze E; de Cristo Soares Alves A; Seixas FK; Collares TV; Pohlmann AR; Guterres SS
AAPS PharmSciTech; 2020 Aug; 21(6):229. PubMed ID: 32778976
[TBL] [Abstract][Full Text] [Related]
18. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA.
Jensen DK; Jensen LB; Koocheki S; Bengtson L; Cun D; Nielsen HM; Foged C
J Control Release; 2012 Jan; 157(1):141-8. PubMed ID: 21864597
[TBL] [Abstract][Full Text] [Related]
19. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
[TBL] [Abstract][Full Text] [Related]
20. Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system.
Hsu FT; Liu HS; Ali AAA; Tsai PH; Kao YC; Lu CF; Huang HS; Chen CY
Nanomedicine; 2018 Apr; 14(3):1019-1031. PubMed ID: 29391212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
